Press releaseBusiness Wire
Corcept Therapeutics
CORT · NASDAQ
$116.45+$4.35 (+3.88%)TodayMarket closed ·
Prev close $112.10
Latest news
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR)
- News
10 Health Care Stocks With Whale Alerts In Today’s Session
- Press releaseBusiness Wire
Corcept Announces Planned Leadership Transition
- Press releaseBusiness Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
- Press releasePRNewswire
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- NewsPiero Cingari
Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsMohd Haider
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate
- Press releaseBusiness Wire
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- Press releaseBusiness Wire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- News
10 Health Care Stocks With Whale Alerts In Today’s Session
- Press releasePRNewswire
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
- Press releaseBusiness Wire
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
- Press releaseBusiness Wire
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
- Press releaseBusiness Wire
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
- Press releaseBusiness Wire
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
- NewsVandana Singh
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
- News
Corcept Therapeutics Q1 2026 Earnings Call Transcript
- News
Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate
- Press releaseBusiness Wire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Press releaseBusiness Wire
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
- Press releaseBusiness Wire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Press releasePRNewswire
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
- Press releaseBusiness Wire
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
- Press releasePRNewswire
CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
- Press releasePRNewswire
CORT DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Today's Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit
- Press releaseGlobe Newswire
CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st
- Press releaseGlobe Newswire
CORT FINAL DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure
- Press releaseGlobe Newswire
CORT 3-DAY DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure
- Press releaseBusiness Wire
Corcept 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
- NewsAvi Kapoor
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings
- NewsAvi Kapoor
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- NewsAvi Kapoor
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply
- NewsAvi Kapoor
Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- NewsAvi Kapoor
Dow Falls 50 Points; US Initial Jobless Claims Decline
- NewsAvi Kapoor
Cybin, Xpeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.